Antifibrotic therapiesemerging biomarkers as treatment end points

Jayant A. Talwalkar

Research output: Contribution to journalComment/debatepeer-review

13 Scopus citations


The emergence of novel pharmacologic therapies for hepatic fibrosis holds promise for the management of this condition. Furthermore, novel, biological indicesin addition to liver biopsymay improve our ability to assess the unique pharmacological effects generated by these agents. This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis.

Original languageEnglish (US)
Pages (from-to)59-61
Number of pages3
JournalNature Reviews Gastroenterology and Hepatology
Issue number1
StatePublished - Jan 2010

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Antifibrotic therapiesemerging biomarkers as treatment end points'. Together they form a unique fingerprint.

Cite this